Has Mah Mekolle received payments from drug or device companies?

Yes. Drug and device makers reported $3,214 in general payments to Mah Mekolle across 114 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Mah Mekolle did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Mah Mekolle come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Mah Mekolle

Psychiatric/Mental Health · Lehi, UTNPI 1366100786

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $2,214 of the $3,214 with a category attached, or 68.9%. 22 manufacturers reported payments, led by AbbVie at 46.6% of the total. 2025 is the largest year on record at $1,512, 3.4 times the $442 reported in 2022.

$3,214in general payments, 2019–2025

Across 114 payments — averaging $28.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$1K
Supernus Pharmaceuticals, Inc.$550
Lundbeck LLC$189
Takeda Pharmaceuticals U.S.A., Inc.$126
Otsuka America Pharmaceutical, Inc.$107
Neurocrine Biosciences, Inc.$105
plus $638 from 16 others

What the payments were for

Speaking & faculty fees$1,00031%
Food & beverage$2,21469%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie	39	$1,499
Supernus Pharmaceuticals, Inc.	14	$550
Lundbeck LLC	11	$189
Takeda Pharmaceuticals U.S.A., Inc.	7	$126
Otsuka America Pharmaceutical, Inc.	7	$107
Neurocrine Biosciences, Inc.	4	$105
Axsome Therapeutics, Inc.	4	$92
Ironshore Pharmaceuticals Inc.	4	$91
Vanda Pharmaceuticals Inc.	3	$76
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)	4	$75
Alkermes, Inc.	2	$45
Corium, LLC	3	$42
Tris Pharma Inc	2	$40
Biogen	2	$31
Tempus AI, Inc	1	$24
Merck	1	$19
Idorsia Pharmaceuticals US Inc	1	$18
Collegium Pharmaceutical, Inc.	1	$18
Noven Therapeutics, LLC	1	$18
Soleno Therapeutics, Inc.	1	$17
Biohaven Pharmaceutical Holding Company Ltd.	1	$16
Bausch Health US, LLC	1	$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

VRAYLAR$1,000
QELBREE$357

How this compares

$3,214 in reported general payments places this provider in the 85th percentile of 393 psychiatric/mental health providers in Utah.

See all psychiatric/mental health providers in Utah →

Other psychiatric/mental health in Lehi

Tanner ManwaringLehi$4K
Fernanda JohnstonLehi$3K
Bret HafenLayton$381K
Alberto SouzaSaint George$114K
Anthony BrowningOrem$32K
Debra HainRiverton$29K
Kristin BarberSalt Lake City$28K
Briana TerrySalt Lake City$14K
Paige MarshallSaint George$13K
Derick MoodySpringville$8K

See the full list for Utah →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →